Rapaka, Rao S.

Drug Addiction

Rapaka, Rao S. - Drug Addiction, e-kirja


E-kirja, PDF, Adobe DRM-suojattu
ISBN: 9780387766782

TulostusEi sallittu
Kopioi leikepöydälleEi sallittu

Table of contents

I. General Topics

1. DARPP-32 Mediates the Actions of Multiple Drugs of Abuse
Per Svenningsson, Angus C. Nairn, Paul Greengard

2. Drug Discovery From Natural Sources
Young-Won Chin, Marcy J. Balunas, Hee Byung Chai, A. Douglas Kinghorn

3. Computational Methods in Drug Design: Modeling G Protein-Coupled Receptor Monomers, Dimers, and Oligomers
Patricia H. Reggio

4. Symbiotic Relationship of Pharmacogenetics and Drugs of Abuse
Joni L. Rutter

5. Monoclonal Antibody Form and Function: Manufacturing the Right Antibodies for Treating Drug Abuse
Eric Peterson, S. Michael Owens, Ralph L. Henry

6. Cocaine- and Amphetamine-Regulated Transcript Peptides Play a Role in Drug Abuse and Are Potential Therapeutic Targets
Michael J. Kuhar, Jason N. Jaworski, George W. Hubert, Kelly B. Philpot, Geraldina Dominguez

7. RNAi-Directed Inhibition of DC-SIGN by Dendritic Cells: Prospects for HIV-1 Therapy
Madhavan P. N. Nair, Jessica L. Reynolds, Supriya D. Mahajan, Stanley A. Schwartz, Ravikumar Aalinkeel, B. Bindukumar, Don Sykes

8. Viewing Chemokines as a Third Major System of Communication in the Brain
Martin W. Adler, Ellen B. Geller, Xiaohong Chen, Thomas J. Rogers

9. Targeting the PDZ Domains of Molecular Scaffolds of Transmembrane Ion Channels
Andrea Piserchio, Mark Spaller, Dale F. Mierke

10. Neuronal Nicotinic Acetylcholine Receptor Expression and Function on Nonneuronal Cells
Lorise C. Gahring, Scott W. Rogers

II. Transporters & Stimulants & Hallucinogens

11. Role of Monoamine Transporters in Mediating Psychostimulant Effects
Evan L. Riddle, Annette E. Fleckenstein, Glen R. Hanson

12. Development of the Dopamine Transporter Selective RTI-336 as a Pharmacotherapy for Cocaine Abuse
F. Ivy Carroll, James L. Howard, Leonard L. Howell, Barbara S. Fox, Michael J. Kuhar

13. Serotonin Transporters: Implications for Antidepressant Drug Development
Kellie J. White, Crystal C. Walline, Eric L. Barker

14. Recent Advances for the Treatment of Cocaine Abuse: Central Nervous System Immunopharmacotherapy
Tobin J. Dickerson, Kim D. Janda

15. ? Opioids as Potential Treatments for Stimulant Dependence
Thomas E. Prisinzano, Kevin Tidgewell, Wayne W. Harding

16. Regulation of Monoamine Transporters: Influence of Psychostimulants and Therapeutic Antidepressants
Lankupalle D. Jayanthi, Sammanda Ramamoorthy

17. Hallucinogen Actions on 5-HT Receptors Reveal Distinct Mechanisms of Activation and Signaling by G Protein-Coupled Receptors
Harel Weinstein

18. Recognition of Psychostimulants, Antidepressants, and Other Inhibitors of Synaptic Neurotransmitter Uptake by the Plasma Membrane Monoamine Transporters
Christopher K. Surratt, Okechukwu T. Ukairo, Suneetha Ramanujapuram

19. Dual Dopamine/Serotonin Releasers as Potential Medications for Stimulant and Alcohol Addictions
Richard B. Rothman, Bruce E. Blough, Michael H. Baumann

20. Receptors of Mammalian Trace Amines
Anita H. Lewin

III. Drug Design: Nicotine, Opioids and Related Ligands

21. The Role of Crystallography in Drug Design
Jeffrey R. Deschamps

22. Opioid Peptide-Derived Analgesics
Peter W. Schiller

23. Opioid Ligands with Mixed µ/d Opioid Receptor Interactions: An Emerging Approach to Novel Analgesics
Subramaniam Ananthan

24. Small-Molecule Agonists and Antagonists of the Opioid Receptor-Like Receptor (ORL1, NOP): Ligand-Based Analysis of Structural Factors Influencing Intrinsic Activity at NOP
Nurulain Zaveri, Faming Jiang, Cris Olsen, Willma Polgar, Lawrence Toll

25. Kappa Opioid Antagonists: Past Successes and Future Prospects
Matthew D. Metcalf, Andrew Coop

26. In Vitro and Direct In Vivo Testing of Mixture-Based Combinatorial Libraries for the Identification of Highly Active and Specific Opiate Ligands
Richard A. Houghten, Colette T. Dooley, Jon R. Appel

27. Current Status of Immunologic Approaches to Treating Tobacco Dependence: Vaccines and Nicotine-Specific Antibodies
Mark G. LeSage, Daniel E. Keyler, Paul R. Pentel

28. New Paradigms and Tools in Drug Design for Pain and Addiction
Victor J. Hruby, Frank Porreca, Henry I. Yamamura, Gordon Tollin, Richard S. Agnes, Yeon Sun Lee, Minying Cai, Isabel Alves, Scott Cowell, Eva Varga, Peg Davis, Zdzislaw Salamon, William Roeske, Todd Vanderah, Josephine Lai

IV. Opioids: General

29. Neuropeptide-Processing Enzymes: Applications for Drug Discovery
Lloyd D. Fricker

30. CNS Drug Delivery: Opioid Peptides and the Blood-Brain Barrier
Ken A. Witt, Thomas P. Davis

31. Cell-Permeable, Mitochondrial-Targeted, Peptide Antioxidants
Hazel H. Szeto

32. Targeting Opioid Receptor Heterodimers: Strategies for Screening and Drug Development
Achla Gupta, Fabien M. Décaillot, Lakshmi A. Devi

33. Homology Modeling of Opioid Receptor-Ligand Complexes Using Experimental Constraints
Irina D. Pogozheva, Magdalena J. Przydzial, Henry I. Mosberg

34. Molecular Recognition of Opioid Receptor Ligands
Brian E. Kane, Bengt Svensson, David M. Ferguson

35. Role of Morphine’s Metabolites in Analgesia: Concepts and Controversies
Erica Wittwer, Steven E. Kern

36. Mu Opioid Receptor Regulation and Opiate Responsiveness
Kirsten M. Raehal, Laura M. Bohn

37. Agmatine: Biological Role and Therapeutic Potentials in Morphine Analgesia and Dependence
Soundar Regunathan

V. Cannabinoid

38. The Therapeutic Potential of Drugs that Target Cannabinoid Receptors or Modulate the Tissue Levels or Actions of Endocannabinoids
Roger G. Pertwee

39. Further Advances in the Synthesis of Endocannabinoid-Related Ligands
Anu Mahadevan, Raj K. Razdan

40. Ajulemic Acid (IP-751): Synthesis, Proof of Principle, Toxicity Studies, and Clinical Trials
Sumner Burstein

41. Conformational Characteristics of the Interaction of SR141716A with the CB1 Cannabinoid Receptor as Determined Through the Use of Conformationally Constrained Analogs
Brian F. Thomas, Yanan Zhang, Marcus Brackeen, Kevin M. Page, S. Wayne Mascarella, Herbert H. Seltzman

42. Activation of G-Proteins in Brain by Endogenous and Exogenous Cannabinoids
Steven R. Childers

43. 2-Arachidonoylglycerol (2-AG) Membrane Transport: History and Outlook
Anita Hermann, Martin Kaczocha, Dale G. Deutsch

44. Endocannabinoid Mechanisms of Pain Modulation
Andrea G. Hohmann, Richard L. Suplita


Printing: not available
Clipboard copying: not available

Avainsanat: TECHNOLOGY & ENGINEERING / Biomedical TEC059000

Terveys, kauneus, muoti

Samankaltaisia e-kirjoja